Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multiple Ascending Dose Study with AGMB-129 in Healthy Participants
Details : AGMB-129 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2025
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Agomab Reports Positive Phase 2a Results for AGMB-129 in Crohn’s Disease
Details : AGMB-129 is an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β RI or ALK5), being studied for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : AGMB-129
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $89.0 million
Deal Type : Series D Financing
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
Details : The proceeds from the financing will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129 in patients with fibrostenosing Crohn’s disease (FSCD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $89.0 million
Deal Type : Series D Financing
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2024
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : AGMB-129
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2023
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under phase 1 clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : AGMB-447
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : EQT Life Sciences
Deal Size : $100.0 million
Deal Type : Series C Financing
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
Details : Proceeds will support Phase 2 candidate AGMB-129/ORG-129 for Fibrostenosing Crohn’s Disease and development of a highly innovative pipeline of anti-fibrotic and regenerative therapies, including AGMB-447 for idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 10, 2023
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : EQT Life Sciences
Deal Size : $100.0 million
Deal Type : Series C Financing
Lead Product(s) : AGMB-129
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2023
Lead Product(s) : AGMB-129
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable